HDRP Newsletter, April 2019

Funding

*NEW* Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (R01 Clinical Trial Required), RFA-CA-19-035

Contact: Michelle Mollica
Application Due Date: June 28, 2019
Pre-application webinar will be held on May 3, 2019. More information here.

*NEW* Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required), RFA-CA-19-033

Contact: Sandra Mitchell
Application Due Date: January 3, 2019
Archived webinar available here.

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional), PAR-19-136

Contact: Ashley Wilder Smith
Next Submission Date: June 5, 2019
Expiration Date: January 8, 2022

Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional), PA-18-932

Contact: Erica Breslau
Next Submission Date: June 5, 2019
Expiration Date: January 8, 2022

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional), PAR-18-869

Contact: Scott Rogers
Next Submission Date: November 7, 2019
Expiration Date: March 9, 2021
Archived webinar available here.

For more information about funding, please visit our website.

Grants Announcements

NIH Highlights Support for Data Science Research through the Academic Research Enhancement Award (AREA) Program

This Notice highlights the role of the AREA program in exposing undergraduate students to data-science research and engaging a broader community in this area of science.

Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations

This Notice encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations. For a related administrative supplement opportunity, please see here.

Upcoming Events and Presentations

Healthcare Teams Cyber Discussion: Communication and Decision-making in Multidisciplinary Tumor Boards

April 30, 2019
Register Here

Pre-Application Webinar: Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care, RFA-CA-19-035

May 3, 2019
Register Here

AcademyHealth 2019 Annual Research Meeting

June 2-4
Washington, DC
Numerous HDRP staff will be in attendance.

Data and Resources

Redesigned HDRP Website

We are pleased to share that we have recently launched our new and improved website at https://healthcaredelivery.cancer.gov! We hope that this redesigned site will offer more intuitive and improved navigation for finding information that is most critical to our extramural community, including funding opportunities as well as available data and tools for research. We invite you to regularly check the “What’s New” section of our homepage for news and updates and hope that you will connect with us on Twitter/X and through our email listserv where you will receive our quarterly E-Newsletter and other frequent announcements.

Additional PRO-CTCAE Language Translations

The Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a patient-reported outcome measurement system developed to characterize the frequency, severity and interference of 78 symptomatic treatment toxicities. With the addition of four new language translations, including Turkish, Malay, Romanian, and Simplified Chinese, the PRO-CTCAE is now available in 22 languages! See here for more information about PRO-CTCAE.

New SEER-MHOS Data Available

The Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey (SEER-MHOS) linked database is a resource designed to improve understanding of the health-related quality of life of cancer patients and survivors enrolled in Medicare Advantage Organizations. With the addition of cohort 18, SEER-MHOS now contains data on over 180,000 cancer patients and over 2.5 million MHOS beneficiaries with no history of cancer. In addition, Medicare Part D prescription drug enrollment and claims data (2007-2016) are now available and may be requested as part of the SEER-MHOS data use agreement application process. See here for more information about SEER-MHOS.